Items Tagged ‘Breast Cancer’

July 23, 2018

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer

By

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. The FDA also approved Kisqali in combination with fulvestrant for the […]

View full entry

Tags: Breast Cancer, News


July 9, 2018

Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients

By

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American […]

View full entry

Tags: Breast Cancer, Dana Farber Cancer Center, Harvard, News, premenopausal breast cancer treatment


June 21, 2018

U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation

By

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which compared talazoparib to chemotherapy in patients with inherited BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. About Talazoparib Talazoparib is an investigational anti-cancer […]

View full entry

Tags: Breast Cancer, News


April 19, 2018

Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer

By

CancerConnect News: According to an Italian research team the three aromatase inhibitors approved for the treatment of postmenopausal hormone receptor–positive early stage breast cancer have no significant differences in effectiveness or safety, For the study, 3697 postsurgical patients with invasive hormone receptor–positive breast cancer were enrolled from 76 Italian public healthcare institutions between March 9, […]

View full entry

Tags: anastrozole, Arimidex, aromasin, Breast Cancer, exemestane, Femara, hormone-receptor positive, letrozole, News, switch schedule


March 26, 2018

FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer

By

CancerConnect News: On December 20, 2017, the Food and Drug Administration granted regular approval to Perjeta (pertuzumab) for use in combination with Herceptin (trastuzumab) and chemotherapy as adjuvant treatment of patients with HER2-positive early stage breast cancer at high risk of recurrence. About Perjeta Breast cancer is the second leading cause of cancer-related death among […]

View full entry

Tags: Breast Cancer, HER-2, neu positive, News, perjeta, pertuzumab


March 20, 2018

At-home Genetic Testing may be Convenient, but it isn’t Complete

By

March 14, 2018 https://www.statnews.com/2018/03/14/genetic-testing-23andme-brca/   Home delivery for everything from fresh produce to custom-selected clothing has become a way of life for many Americans. While most home-delivery conveniences are generally changing our lives for the better — giving us more time and choices — at-home genetics kits that reveal information about the risk of developing […]

View full entry

Tags: 23andme, brca, Breast Cancer, genetic testing, News


March 12, 2018

FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. About VerzenioTM Verzenio is an inhibitor of cyclin-dependent kinases […]

View full entry

Tags: 4 & 6, Breast Cancer, CDK, inhibitor of cyclin-dependent kinases, News, Verzenio


February 21, 2018

Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer

By

A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer (TNBC), according to new research published by a multi-institutional team of researchers.1,2 Although TNBC represents just 10-15 percent of all breast diagnoses, the disease is responsible for 35 […]

View full entry

Tags: Breast Cancer, Liquid Biopsy, News, Triple Negative Breast Cancer


February 13, 2018

Kisqali Combination Promising for Pre-menopausal Hormone Receptor Positive Breast Cancer

By

CancerConnect News: The CDK4/6 inhibitor Kisqali (ribociclib) has been given breakthrough status by the US Food and Drug Administration as an initial endocrine-based treatment for of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. Results from […]

View full entry

Tags: Breast Cancer, CDK4/6 inhibitor, kisqali, News, ribociclib, treatment


February 12, 2018

Five Common Sign & Symptoms of Breast Cancer

By

CancerConnect News: Breast cancer is a cancer that originates in the area of the breast, where cells replicate too quickly, causing a tumor. Breast cancer is most common in women, but I can also occur in men. Breast cancer is caused by an abnormality that is genetic, but only a very low percentage of such […]

View full entry

Tags: Breast Cancer, breast cancer screening, News, signs and symptoms


February 5, 2018

Breast Cancer Treatments May Increase Risk of Heart Disease

By

American Heart Association Scientific Statement Statement Highlights: Some breast cancer therapies can damage the heart and healthcare providers should carefully monitor breast cancer treatment effects on the heart. Breast cancer survivors, especially older women, are more likely to die from cardiovascular diseases such as heart failure rather than breast cancer. Breast cancer patients may be […]

View full entry

Tags: Breast Cancer, News


January 15, 2018

Lynparza Slows Spread of Inherited Breast Cancer Caused by BRCA Mutations: First Drug Approved for BRCA Breast Cancer

By

CancerConnect News: The US Food and Drug Administration (FDA) has extended the approval of Lynparza (olaparib) to include the treatment of metastatic breast cancer in patients who carry the specific inherited BRCA mutation.  These patients can be identified by using the FDA-approved genetic test, BRACAnalysis CDx (Myriad Genetic Laboratories). About BRCA Breast Cancer Breast cancer […]

View full entry

Tags: brca, Breast Cancer, clinical trial, lynparza, News, olaparib, OlympiAD, PARP Inhibitors


January 10, 2018

Updated Keytruda®/Halaven® Report Encouraging for Treatment of Triple Negative Breast Cancer

By

CancerConnect News: The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced following prior therapies. Results of this treatment combination were initially presented at the 2016 annual San Antonio Breast Cancer Symposium (SABCS) and just updated at […]

View full entry

Tags: Breast Cancer, News


January 5, 2018

Start 2018 Right: Plan for Cancer Screening and Save Lives!

By

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before it causes symptoms and when it may be more easily treatable.  Screening tests are not available for every type of […]

View full entry

Tags: breast, Breast Cancer, cancer screening, colon, Colon Cancer, lung, Lung Cancer, News, Skin Cancer


December 27, 2017

Oral Contraceptive Use Still Linked to Breast Cancer

By

Women who rely on birth control pills or contraceptive devices that release hormones face a small but significant increase in the risk for breast cancer, according to a large study published in the New England Journal of Medicine.1 This study is the first to examine the risks associated with current formulations of birth control pills […]

View full entry

Tags: birth control, Breast Cancer, News, oral contraceptives